FDA warned Extrapharmacy.ru for selling unapproved, mislabeled prescription drugs, including COVID-19 treatments, to U.S. consumers online.
What happened
FDA reviewed the website www.extrapharmacy.ru on December 13, 2021. It found drugs offered for sale to U.S. consumers, including Plaquenil (hydroxychloroquine) and Areplivir (favipiravir), promoted for COVID-19 and other diseases such as lupus, rheumatoid arthritis, and malaria. FDA said these are unapproved new drugs and misbranded (mislabeled) because their labeling lacks adequate directions for use.
What FDA found
The website sells prescription drugs that FDA has not approved for sale in the U.S., including products promoted for COVID-19.
Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The drug labels do not give adequate directions for safe use by a layperson, so FDA calls them misbranded.
Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]FDA says the company is causing unapproved and misbranded drugs to enter interstate commerce, which the law prohibits.
Sections 301(a) and 301(d) of the FD&C Act [21 U.S.C. § 331(a), § 331(d)]The site offers Plaquenil (hydroxychloroquine) made by Sanofi and claims it treats malaria, lupus, and rheumatoid arthritis, but FDA has no approved application for that product and has not approved hydroxychloroquine for COVID-19.
Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The site offers Areplivir (favipiravir) made by Promomed and claims it inhibits SARS-CoV-2 and gives a COVID-19 dosing regimen, but FDA has no approved application for that product.
Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]Because the drugs are not approved in the U.S., they do not qualify for the exemption from adequate-directions labeling for approved drugs.
21 CFR 201.115(a)
What FDA wants
FDA tells the company to stop selling the unapproved and misbranded drugs and to email FDA within 48 hours with the specific steps taken to correct the violations and prevent recurrence, including supporting documents.
Who should pay attention
- U.S. consumers who buy prescription drugs from foreign websites
- online pharmacies and telehealth sellers
- companies that supply or advertise COVID-19 products
This is a summary. Read the original letter on fda.gov.